A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol

Roland Buhl,1 Michael Dreher,2 Stephanie Korn,1 Christian Taube,3 Christian Stock,4 Christoph M Zehendner,5 Anke Kondla,5 Claus F Vogelmeier6 1Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 2Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care,...

Full description

Bibliographic Details
Main Authors:	Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-10-01
Series:	International Journal of COPD
Subjects:	copd tiotropium/olodaterol spiolto® respimat® triple therapy lama/laba/ics
Online Access:	https://www.dovepress.com/a-non-interventional-study-of-tiotropiumolodaterol-versus-any-triple-c-peer-reviewed-article-COPD

Similar Items

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease
by: S. K. Zyryanov, et al.
Published: (2018-04-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
by: LaForce C, et al.
Published: (2018-06-01)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting
by: Steinmetz KO, et al.
Published: (2019-07-01)

Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations
by: Tan CK, et al.
Published: (2016-09-01)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
by: Beeh KM, et al.
Published: (2016-02-01)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
by: Hsieh MJ, et al.
Published: (2022-04-01)

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
by: Hoogendoorn M, et al.
Published: (2019-02-01)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
by: Lan Y, et al.
Published: (2023-09-01)

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
by: Sauer R, et al.
Published: (2016-04-01)

Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study
by: Kawachi S, et al.
Published: (2019-05-01)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
by: Mahler DA, et al.
Published: (2021-08-01)

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients
by: Valipour A, et al.
Published: (2019-10-01)

Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study
by: Valipour A, et al.
Published: (2021-03-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Effects of baseline symptom burden on treatment response in COPD
by: Martinez FJ, et al.
Published: (2019-01-01)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01)

Tiotropium/Olodaterol treatment reduces cigarette smoke extract-induced cell death in BEAS-2B bronchial epithelial cells
by: Cheng-hsiung Chen, et al.
Published: (2020-10-01)

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
by: Shigeo Muro, et al.
Published: (2021-06-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®
by: Dekhuijzen PNR, et al.
Published: (2016-08-01)

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
by: Ariel A, et al.
Published: (2017-12-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
by: Sethi S, et al.
Published: (2023-04-01)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
by: Averell CM, et al.
Published: (2019-10-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Prevention of copd exacerbations. Focus on dual bronchodilators
by: V. V. Arkhipov
Published: (2018-10-01)

Is ‘GOLD’ standard for the management of COPD in clinical practice?
by: Barbara Yawn
Published: (2012-11-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

A comparison of tiotropium, long-acting β2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
by: Christian Vogelberg, et al.
Published: (2020-01-01)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
by: Requena G, et al.
Published: (2023-07-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment
by: Bruno Balbi
Published: (2015-08-01)

The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
by: Tarek M. Mostafa, et al.
Published: (2021-01-01)

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol
by: Richeldi L, et al.
Published: (2021-01-01)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
by: Bourbeau J, et al.
Published: (2021-03-01)